Amivantamab monotherapy was assessed in a cohort of EGFR exon 20 insertion mutant NSCLC after progression on platinum-based chemotherapy (median prior lines of therapy was 2) and included an efficacy population (n = 81) and a safety population (n = 114) with patients enrolled across sites from South Korea, Japan and the United States. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.